

Ref: 30/SE/LC/2026-27

Date: August 7, 2026

Scrip Code BSE: 544122
NSE: ENTERO
ISIN: INE010601016

To,

**Head, Listing Compliance Department
BSE Limited**

Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400001

**Head, Listing Compliance Department
National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on August 7, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI LODR Regulations**”), we hereby inform you that the Board of Directors of the Company, at its meeting held today, inter alia, considered and approved the following:

- a) Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, along with Limited Review Reports with unmodified opinion thereon, issued by the Statutory Auditors of the Company, are enclosed as **Annexure**, pursuant to Regulation 33 of SEBI LODR.
- b) Reconstituted the following committees of the Board of Directors, with effect from August 25, 2026, consequent upon the completion of the tenure of Rajesh Shashikant Dalal (DIN: 03504969) as a Non-Executive Independent Director on August 24, 2026:

Audit Committee:

Sr. No.	Name of Directors	Designation	Chairperson/ Member
1	Sandhya Gadkari Sharma	Non- Executive Independent Director	Chairperson
2	Sujesh Vasudevan	Non-Executive Independent Director	Member
3	Prabhat Agrawal	Managing Director & CEO	Member

Nomination and Remuneration Committee:

Sr. No.	Name of Directors	Designation	Chairperson/ Member
1	Sandhya Gadkari Sharma	Non- Executive Independent Director	Chairperson
2	Sujesh Vasudevan	Non-Executive Independent Director	Member
3	Arun Sadhanandham	Non-Executive Nominee Director	Member

Stakeholders Relationship Committee:

Sr. No.	Name of Directors	Designation	Chairperson/ Member
1	Sujesh Vasudevan	Non- Executive Independent Director	Chairperson
2	Arun Sadhanandham	Non-Executive Nominee Director	Member
3	Prem Sethi	Whole Time Director & COO	Member

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003.
Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra.
Tel.: 022-26529100 / 69019100, CIN: L74999HR2018PLC072204

Further to our intimation letter dated June 23, 2026, bearing reference no. 15/SE/LC/2026-27 and pursuant to the Company's Code of Fair Disclosure of Unpublished Price Sensitive Information, framed under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company, shall open after expiry of 48 hours from disclosure the financial results.

The above intimation is also being made available on the website of the Company at www.enterohealthcare.com

The Board Meeting commenced at 01:30 P.M. (IST) and concluded at 03:45 P.M. (IST).

You are requested to take the same on record.

Yours faithfully,
For **Entero Healthcare Solutions Limited**

Sanu Kapoor
Vice President- Group General Counsel,
Company Secretary & Compliance Officer



Entero Healthcare Solutions Limited

Registered Office: Plot No. I-35, Building-B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra

CIN:L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com

Website: www.enterohealthcare.com

Statement of unaudited Standalone Financial Results for the quarter ended 30 June 2026

(Rs. in Millions, except per equity share data)

Sr. No.	Particulars	Quarter ended			Year ended
		30 June 2026 (Unaudited)	31 March 2026 (Audited) (refer note 6)	30 June 2025 (Unaudited)	31 March 2026 (Audited)
1	Income				
	a) Revenue from operations	832.66	789.32	793.52	3,482.41
	b) Other income	231.45	399.56	262.88	1,137.23
	Total Income	1,064.11	1,188.88	1,056.40	4,619.64
2	Expenses				
	a) Purchase of Stock-in-trade	568.13	495.29	959.13	2,780.65
	b) Changes in inventories of Stock-in-trade	161.05	253.16	(258.23)	356.41
	c) Employee benefits expense	122.94	144.33	139.78	578.72
	d) Finance costs	57.42	26.04	5.94	46.08
	e) Depreciation and amortisation expense	31.07	27.78	28.23	117.22
	f) Other expenses	77.45	121.90	89.91	393.73
	Total Expenses	1,018.06	1,068.50	964.76	4,272.81
3	Profit before exceptional items and tax (1) - (2)	46.05	120.38	91.64	346.83
4	Exceptional Items	-	-	-	44.97
5	Profit before tax (3) - (4)	46.05	120.38	91.64	301.86
6	Tax expenses				
	Current tax (including tax expense of earlier year)	2.20	1.15	-	89.06
	Deferred tax charge/(credit)	9.28	(14.93)	22.07	(55.95)
	Total tax expenses	11.48	(13.78)	22.07	33.11
7	Profit for the period/year (5) - (6)	34.57	134.16	69.57	268.75
8	Other comprehensive income				
	Items that will not be reclassified subsequently to profit and loss				
	Remeasurement gain / (loss) on defined benefit plan	(0.94)	(2.86)	0.39	(3.75)
	Income tax effect on above	0.24	0.72	(0.10)	0.94
	Total other comprehensive income	(0.70)	(2.14)	0.29	(2.81)
9	Total comprehensive income (7) + (8)	33.87	132.02	69.86	265.94
10	Paid-up equity share capital (face value - Rs. 10 per share)	435.23	435.11	435.09	435.11
11	Other equity				16,395.25
12	Earnings per share (Face value of Rs.10 each) basic- (Rs.)*	0.79	3.08	1.60	6.18
	Earnings per share (Face value of Rs.10 each) diluted - (Rs.)*	0.79	3.08	1.60	6.17

(*not annualised for the quarters)

See accompanying notes to the unaudited standalone financial results





Entero Healthcare Solutions Limited

Registered Office: Plot No. I-35, Building-B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra

CIN: L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com


Website: www.enterohealthcare.com

NOTES:

- 1 The unaudited standalone financial results are prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', the provisions of the Companies Act, 2013 (the Act), and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05 July 2016, as amended. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited standalone financial results of Entero Healthcare Solutions Limited ("the Company") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 7 August 2026. The statutory auditors have expressed an unmodified conclusion on these unaudited standalone financial results.
- 2 The Company operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Company has only one reportable segment as per Ind AS 108 "Operating Segments".
- 3 During the quarter ended 30 June 2026, the Company has subscribed to the Optionally Convertible Debenture ("OCD") issued by its subsidiaries, detailed as follows:

Name of the entity	Unit number	Date of issuance	Issue price
Saurashtra Medisolutions Private Limited	36,250	9 May 2026	3,300
Sri Parshva Pharma Distributors Private Limited	38,000	17 April 2026	8,400
S.S. Pharma Traders Private Limited	4,000	22 May 2026	55,000
Avenues Pharma Distributors Private Limited	62,500	18 April 2026	5,600
- 4 During the quarter ended 30 June 2026, the Company has allotted 12,135 equity shares of Rs.10 each at a premium of Rs. 794 per share aggregating to Rs. 9.76 million pursuant to exercise of employee stock options
- 5 During the quarter ended 30 June 2026, the Company has granted 24,800 employee stock options under Entero Employee Stock Option Plan 2023.
- 6 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and limited reviewed figures up to nine months ended 31 December 2025.
- 7 The above unaudited standalone financial results of the Company are available on the website of the Company (www.enterohealthcare.com) and on the websites of NSE (www.nseindia.com) and BSE (www.bseindia.com).

Entero Healthcare Solutions Limited


Prabhat Agrawal
CEO & Managing Director
DIN: 07466382
Place: Mumbai
Date: 07 August 2026



Independent Auditor's Review Report on Standalone unaudited financial results of Entero Healthcare Solutions Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Entero Healthcare Solutions Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Entero Healthcare Solutions Limited (hereinafter referred to as 'the Company') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

**VIRENDRA
ZAVERBHAI
KANAK**
Virendra Kanak
Partner
Membership No.: 110811
UDIN: 26110811GOYUJJ2797

Digitally signed by
VIRENDRA ZAVERBHAI
KANAK
Date: 2026.08.07 16:02:16
+05'30'

Place: Mumbai
Date: August 07, 2026



Entero Healthcare Solutions Limited
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra
CIN: L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

Statement of unaudited Consolidated Financial Results for the quarter ended 30 June 2026

(Rs. in Millions, except per equityshare data)

Sr. No.	Particulars	Quarter ended			Year ended
		30 June 2026 (unaudited)	31 March 26 (Audited) (Refer Note 8)	30 June 2025 (unaudited)	31 March 2026 (Audited)
1	Income				
	a) Revenue from operations	19,404.95	19,099.27	14,038.19	65,912.12
	b) Other income	30.07	40.08	58.25	192.37
	Total Income	19,435.02	19,139.35	14,096.44	66,104.49
2	Expenses				
	a) Purchase of Stock-in-trade	17,253.16	16,910.23	12,990.16	59,148.38
	b) Changes in inventories of Stock-in-trade	(61.81)	114.83	(347.68)	(40.08)
	c) Employee benefits expense	694.16	647.62	575.57	2,454.99
	d) Finance costs	205.72	173.11	106.64	543.85
	e) Depreciation and amortisation expense	123.05	147.92	88.69	432.93
	f) Other expenses	549.54	566.17	319.43	1,689.28
	Total Expenses	18,763.82	18,559.88	13,732.81	64,229.35
3	Profit before exceptional items and tax (1) - (2)	671.20	579.47	363.63	1,875.14
4	Exceptional items	-	-	-	81.78
5	Profit before tax (3) - (4)	671.20	579.47	363.63	1,793.36
6	Tax expenses				
	Current tax (including tax expense of earlier year)	176.54	204.10	81.09	594.80
	Deferred tax charge/(credit)	(25.85)	(75.91)	(19.78)	(259.84)
	Total tax expenses	150.69	128.19	61.31	334.96
7	Profit for the period/year (5) - (6)	520.51	451.28	302.32	1,458.40
8	Other comprehensive income				
	Items that will not be reclassified subsequently to profit and loss				
	Remeasurement (losses)/gains on defined benefit plan	(1.74)	(3.78)	1.64	(7.86)
	Income tax effect on above	0.44	0.89	(0.42)	1.95
	Total other comprehensive income	(1.30)	(2.89)	1.22	(5.91)
9	Total comprehensive income (7) + (8)	519.21	448.38	303.54	1,452.49
10	Profit attributable to:				
	Owners of the Company	381.62	280.09	277.99	1,150.42
	Non-controlling interests	138.89	171.19	24.33	307.98
11	Other comprehensive income attributable to:				
	Owners of the Company	(1.28)	(2.94)	0.93	(5.82)
	Non-controlling interests	(0.02)	0.05	0.29	(0.09)
12	Total comprehensive income attributable to:				
	Owners of the Company	380.34	277.15	278.92	1,144.60
	Non-controlling interests	138.87	171.24	24.62	307.89
13	Paid-up equity share capital (face value - Rs. 10 per share)	435.23	435.11	435.09	435.11
14	Other equity				16,450.99
15	Earnings per share (Face value of Rs. 10 each) basic- (Rs.)*	8.77	6.44	6.39	26.44
	Earnings per share (Face value of Rs. 10 each) diluted - (Rs.)*	8.76	6.43	6.38	26.40

(*not annualised for the quarters)

See accompanying notes to the unaudited consolidated financial results





Entero Healthcare Solutions Limited
Registered Office: Plot No. I-35, Building -8, Industrial Area Phase-I, 13/7 Mahura Road, Faridabad, Haryana, 121003
Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kaline, Mumbai-400 098, Maharashtra
 CIN: L74999HR2018PLC072204
 Tel. No : 022-26529100
 Email: info@enterohealthcare.com
 Website: www.enterohealthcare.com

NOTES:

- The unaudited consolidated financial results are prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', the provisions of the Companies Act, 2013 (the Act), and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05 July 2016, as amended. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited consolidated financial results of Entero Healthcare Solutions Limited ("the Holding Company" or "the Company"), and its subsidiaries (the Holding Company along with subsidiaries together referred to as "the Group") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 7 August 2026. The statutory auditors have expressed an unmodified conclusion on these unaudited consolidated financial results.
- The Group operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Group has only one reportable segment as per Ind AS 108 "Operating Segments".
- During the year ended 31 March 2026, the Holding Company has entered into share purchase agreement with following entities, resulting in these entities becoming the subsidiaries of the Company. The figures for the quarter ended 30 June 2026 are not comparable with the corresponding/comparative period since the below mentioned entities have been consolidated from the respective date of share transfer, as mentioned below:

Name of the entity	Date of share transfer	Number of Equity Shares Acquired	% of shareholding
Ramson Medical Distributors Private Limited	30 June 2025	7,00,000	70%
Sai RK Pharma Private Limited	19 July 2025	7,000	70%
Well Wisher Pharma Private Limited	05 September 2025	7,000	70%
Anand Meditink Private Limited	01 October 2025	8,000	80%
Ace Cardiopathy Solutions Private Limited	06 October 2025	1,78,840	60%
Bioaide Technologies Private Limited	26 November 2025	76,032	80%
Anand Chemiceutics Private Limited	07 February 2026	51,510	51.51%

- During the quarter ended 30 June 2026, the Company has allotted 12,135 equity shares of Rs 10 each at a premium of Rs 7.94 per share aggregating to Rs. 9.76 million pursuant to exercise of employee stock options.
- Subsequent to quarter ended 30 June 2026, R S M Pharma Private Limited (Wholly owned Subsidiary of the Company) has subscribed to 100% equity shares of Quorovia Lifesciences Private Limited on 25 July 2026, resulting this entity becoming step down subsidiary of the Company.
- During the quarter ended 30 June 2026, the Company has granted 24,800 employee stock options under Entero Employee Stock Option Plan 2023.
- During the quarter ended 30 June 2026, Sai Pharma Distributors Private Limited (Subsidiary Company of the Company) has entered into business transfer agreement with Vishal Surgicals and Vishal Surgicals & Medicals, having their registered office in Telangana, India. The said transaction is expected to be completed by 31 December 2026.
- The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and limited reviewed figures up to nine months ended 31 December 2025.
- The above unaudited consolidated financial results of the Group are available on the website of the Company (www.enterohealthcare.com) and on the websites of NSE (www.nseindia.com) and BSE (www.bseindia.com).

Entero Healthcare Solutions Limited


 Prabhat Agrawal
 CEO & Managing Director
 DIN: 07466382
 Place: Mumbai
 Date: 07 August 2026



Independent Auditor's Review Report on consolidated unaudited financial results of Entero Healthcare Solutions Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Entero Healthcare Solutions Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Entero Healthcare Solutions Limited (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.
4. This Statement includes the results of the Holding Company and the entities listed in Annexure A.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

6. We did not review the financial information of 4 subsidiaries included in the Statement, whose interim financial information reflects total revenues of Rs. 3,272.51 million, total net profit after tax of Rs. 219.50 million and total comprehensive income of Rs. 219.50 million, for the quarter ended June 30, 2026, respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

7. The Statement includes the interim financial information of 22 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflects total revenue of Rs. 3,956.05 million, total net profit after tax of Rs. 55.02 million and total comprehensive income of Rs. 54.91 million for the quarter ended June 30, 2026, respectively as considered in the Statement. This interim financial information has been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited financial information. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)

Chartered Accountants

ICAI Firm Registration No.105047W/W101187

VIRENDRA

ZAVERBHAI

KANAK

Digitally signed by

VIRENDRA ZAVERBHAI

KANAK

Date: 2026.08.07 16:01:30
+05'30'

Virendra Kanak

Partner

Membership No.: 110811

UDIN: 26110811OPRUHL4578

Place: Mumbai

Date: August 07, 2026

MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

“Annexure A to the Independent Auditor’s Review Report on Consolidated unaudited financial results of Entero Healthcare Solutions Limited for the quarter ended June 30, 2026 pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended”.

Sr. No.	Name of the entity	Relationship with Holding Company
1	Novacare Healthcare Solutions Private Limited	Wholly owned Subsidiary Company
2	R S M Pharma Private Limited	Wholly owned Subsidiary Company
3	Avenues Pharma Distributors Private Limited	Wholly owned Subsidiary Company
4	Chirag Medicare Solutions Private Limited	Wholly owned Subsidiary Company
5	Chethana Pharma Private Limited	Wholly owned Subsidiary Company
6	Jaggi Enterprises Private Limited	Wholly owned Subsidiary Company
7	Vasavi Medicare Solutions Private Limited	Wholly owned Subsidiary Company
8	SVMED Solutions Private Limited	Wholly owned Subsidiary Company
9	Millennium Medisolutions Private Limited	Wholly owned Subsidiary Company
10	G.S. Pharmaceutical Distributors Private Limited	Wholly owned Subsidiary Company
11	Getwell Medicare Solution Private Limited	Wholly owned Subsidiary Company
12	Galaxystar Pharma Distributors Private Limited	Wholly owned Subsidiary Company
13	Barros Enterprises Private Limited	Wholly owned Subsidiary Company
14	Sesha Balajee Medisolutions Private Limited	Wholly owned Subsidiary Company
15	Rada Medisolutions Private Limited	Wholly owned Subsidiary Company
16	Sri Parshva Pharma Distributors Private Limited	Wholly owned Subsidiary Company
17	Sri Rama Pharmaceutical Distributors Private Limited	Wholly owned Subsidiary Company
18	Western Healthcare Solutions Private Limited	Wholly owned Subsidiary Company
19	Chhabra Healthcare Solutions Private Limited	Wholly owned Subsidiary Company
20	Chethana Healthcare Solutions Private Limited	Wholly owned Subsidiary Company
21	S.S. Pharma Traders Private Limited	Wholly owned Subsidiary Company
22	Sundarlal Pharma Distributors Private Limited	Wholly owned Subsidiary Company
23	New Siva Agencies Private Limited	Wholly owned Subsidiary Company
24	Saurashtra Medisolutions Private Limited	Wholly owned Subsidiary Company
25	New RRPD Private Limited	Wholly owned Subsidiary Company
26	Sree Venkateshwara Medisolutions Private Limited	Wholly owned Subsidiary Company
27	SVS Lifesciences Private Limited	Wholly owned Subsidiary Company
28	Swami Medisolutions Private Limited	Wholly owned Subsidiary Company
29	Atreja Healthcare Solutions Private Limited	Wholly owned Subsidiary Company
30	Calcutta Medisolutions Private Limited	Wholly owned Subsidiary Company
31	City Pharma Distributors Private Limited	Wholly owned Subsidiary Company
32	Curever Pharma Private Limited	Wholly owned Subsidiary Company
33	Entero R.S Enterprises Private Limited	Wholly owned Subsidiary Company
34	Dhanvanthri Super Speciality Private Limited	Subsidiary Company
35	Avenir Lifecare Pharma Private Limited	Subsidiary Company
36	Devi Pharma Wellness Private Limited	Wholly owned Subsidiary Company

MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

Sr. No.	Name of the entity	Relationship with Holding Company
37	Gourav Medical Agencies Private Limited	Subsidiary Company
38	Srinivasa Lifecare Private Limited	Subsidiary Company
39	Sai Pharma Distributor Private Limited	Subsidiary Company
40	Peerless Biotech Private Limited	Subsidiary Company
41	Ujjain Maheshwari Pharma Distributor Private Limited	Wholly owned Subsidiary Company
42	Ramson Medical Distributors Private Limited	Subsidiary Company
43	Sai RK Pharma Private Limited	Subsidiary Company
44	Well Wisher Pharma Private Limited	Subsidiary Company
45	Anand Medilink Private Limited	Subsidiary Company
46	Ace Cardiopathy Solutions Private Limited	Subsidiary Company
47	Bioaide Technologies Private Limited	Subsidiary Company
48	Anand Chemiceutics Private Limited	Subsidiary Company